telomirpharma.com - רווח החברה לפני מסים, ריבית ופחת TELO

The expansion of the small molecule pipeline for telomere control at Telomir Pharmaceuticals (TELO) stimulates strict oversight of chemical formula delivery to laboratories. Aggregate EBITDA clearly confirms this correlation, where 0.00 shows the value of this parameter. The result is the creation of a comprehensive longevity ecosystem that radically transforms methods for treating age-related pathologies and bodily recovery.

This indicator is calculated as the difference between daily revenue from core operations and direct operating expenses, allowing for an assessment of the business's real liquidity excluding debt obligations. An analysis of operating cash flow before interest and taxes confirms the effectiveness of the outsourcing strategy at Telomir Pharmaceuticals (TELO), minimizing capital expenditures on laboratories and reducing the risk of capital drawdown during the scaling of research.